|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500114444 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-11 17:45:34 |
|
注册时间: Date of Registration: |
2025-12-11 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
甲状腺乳头状癌颈侧区淋巴结转移相关危险因素分析及nomogram建立 |
|
Public title: |
Analysis of risk factors associated with lymph node metastasis in the cervical lateral zone of papillary thyroid carcinoma and establishment of a nomogram |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
甲状腺乳头状癌颈侧区淋巴结转移相关危险因素分析及nomogram建立 |
|
Scientific title: |
Analysis of risk factors associated with lymph node metastasis in the cervical lateral zone of papillary thyroid carcinoma and establishment of a nomogram |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
宫毅 |
研究负责人: |
宫毅 |
|
Applicant: |
Gong Yi |
Study leader: |
Gong Yi |
|
申请注册联系人电话: Applicant telephone: |
+86 13574848969 |
研究负责人电话: Study leader's telephone: |
+86 13574848969 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
13574848969@168.com |
研究负责人电子邮件: Study leader's E-mail: |
gongyi5226@csu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省长沙市芙蓉区人民中路139号 |
研究负责人通讯地址: |
湖南省长沙市芙蓉区人民中路139号 |
|
Applicant address: |
No.139, Renmin Middle Road, Changsha, Hunan Province, China |
Study leader's address: |
No 139 Renmin Road Furong district |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中南大学湘雅二医院 |
||
|
Applicant's institution: |
The Second Xiangya Hospital of Central South University |
||
|
研究负责人所在单位: |
中南大学湘雅二医院 |
||
|
Affiliation of the Leader: |
Second Xiangya Hospital of CSU |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LYEC2025-K0091 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中南大学湘雅二医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Clinical Research Ethics Committee of the Second Xiangya Hospital, Central South University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-04-14 00:00:00 |
||
|
伦理委员会联系人: |
蒋屏 |
||
|
Contact Name of the ethic committee: |
Jiang Ping |
||
|
伦理委员会联系地址: |
湖南省长沙市芙蓉区人民中路139号 |
||
|
Contact Address of the ethic committee: |
No 139 Renmin Road Furong district |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 731 8529 2476 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
xy2gcpjiang@163.com |
|
研究实施负责(组长)单位: |
中南大学湘雅二医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Second Xiangya Hospital of CSU |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南省长沙市芙蓉区人民中路139号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No 139 Renmin Road Furong district |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
self-finance |
||||||||||||||||||||||
|
Target disease: |
Papillary Thyroid Carcinoma |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
探讨影响甲状腺乳头状癌颈侧区淋巴结转移的相关危险因素并绘制nomogram预测模型。 |
||||||||||||||||||||||
|
Objectives of Study: |
Exploration of risk factors affecting lymph node metastasis in the cervical region of papillary thyroid carcinoma and development of a nomogram prediction model |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 患者年龄在18-80岁; 2.所有患者均为初次手术,且经术后病理检查确诊为PTC; 3.术前实验室资料及影像学资料保存完整且准确。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Patients were aged 18-80 years; |
||||||||||||||||||||||
|
排除标准: |
1.年龄<18岁或>80岁; 2.既往曾行甲状腺手术者; 3.术后病理提示非PTC者; 4.术前影像学资料及实验室资料不全者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients were age <18 years or >80 years; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-03-01 00:00:00至 To 2026-03-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-05-05 00:00:00 至 To 2025-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
国家生物信息中心 (https://ngdc.cncb.ac.cn/gsub/)。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
一、数据采集:通过过 Epidata 软件设计标准化的数据收集表格,确保所有信息(如研究参与者基本信息、术前实验室检验结果、彩超资料、术后病理结果等)按统一格式进行记录。 二、数据管理:所有数据均保存在 Excel 中,数据定期备份,存储在不同的物理位置(如云存储和本地存储),以防止数据丢失。同时采用权限控制机制,确保只有授权人员可以访问和操作研究数据,避免未经授权的人员查看或修改数据。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1.Data collection: A standardized data collection form was designed through Epidata software to ensure that all information (e.g., study participants' basic information, preoperative laboratory test results, ultrasound information, postoperative pathology results, etc.) was recorded in a uniform format. 2.Data management: All data were saved in Excel, and data were regularly backed up and stored in different physical locations (e.g., cloud storage and local storage) to prevent data loss. A privilege control mechanism is also used to ensure that only authorized personnel can access and operate the study data to avoid unauthorized personnel viewing or modifying the data. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |